TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes according to WHO 1999 criteria for at least 3 month~* Insulin treated for at least 1 month~* BMI 25-40~* Age 18-80~* Hb1Ac \< 10%~Exclusion Criteria:~* Hypertension not well regulated~* Serum creatinine \> 130 micromol/l~* Non-diabetic kidney disease~* Disease that may cause invalid hgbA1c measurement~* Substance abuse~* Recent use of Detemir~* Pregnancy or risk of becoming pregnant~* Any condition that may disturb protocol adherence (language barrier etc) urinary albumin \> 30 mg/24hours ( before screening)~* Use of drugs that may influence blood glucose (except oral antidiabetics)~* Use of drugs that may influence sodium balance,i.e diuretics ( tiazides accepted)~* Clinical significant disease that may influence outcome ( cancer etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
- 2 (Type: ACTIVE_COMPARATOR): 8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medical Polypectomy and Predictors of Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female~* 18-75 years of age~* bilateral nasal polyposis Grade 2 and above~* with or without asthma~* with or without atopy or aspirin sensitivity~* written informed consent~Exclusion Criteria:~* unilateral nasal polyposis~* polypoid lesion suspicious of inverted papilloma, malignancy, Wegeners granulomatosis, sarcoidosis~* known or suspected hypersensitivity to fluticasone propionate or any other constituents of the Investigational Medicinal product (IMP).~* Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the subject or which might interfere with the study.~* significant (≥50%)septal deviation~* inability to comply with the requirements of the protocol~* females who are pregnant, lactating or planning to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
- Prednisolone (Type: EXPERIMENTAL): 25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Morphine for Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women (ASA 2)~* Between 18 and 45 years old~* Singleton term pregnancies~* Planned neuraxial anesthesia~Exclusion Criteria:~* Refusal to participate~* Known allergy or contraindication to any medication used in the study~* Significant medical or obstetrical disease (ASA ≥ 3)~* Opioid use disorder~* Chronic pain syndrome~* Daily or near daily opioid use within last 3 weeks.~* Patient receiving a Monoamine oxidase inhibitors (MOAi)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 50 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
- 150 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
- 250 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet the diagnostic criteria for immune thrombocytopenia.~2. Untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years.~3. To show a platelet count \<30 \* 10\^9/L, and with bleeding manifestations.~4. Willing and able to sign written informed consent.~Exclusion Criteria:~1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit.~2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit.~3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study.~4. Current HIV infection or hepatitis B virus or hepatitis C virus infections.~5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)~6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.~7. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.~8. Patients who are deemed unsuitable for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone group (Type: EXPERIMENTAL): Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
- Dexamethasone group (Type: EXPERIMENTAL): DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* De novo native coronary chronic occlusion with a reference diameter equal or superior to 3 mm programmed treatment;~* 100 mg/die oral aspirin treatment for at least 7 days before the procedure;~* Target lesion must be covered with two stent maximum with a maximum length ≤ 33 mm each~* Signed written informed consent~Exclusion Criteria:~* Aspirin, bisulphate clopidogrel, ticlopidine, heparin, contrast agent or heavy metals known allergy that cannot been medically handled;~* Target occlusion localized inside a previously implanted graft~* Target occlusion localized inside a vessel segment previously underwent stent-positioning~* Target occlusion localized inside a vessel with other occlusion not-to-be treated with the target occlusion same stent(s)~* Target occlusion localized inside a vessel with other occlusions need to be treated with balloon angioplasty~* Other techniques than balloon angioplasty target occlusion pre-treatment such as atherectomy, laser intervention or thrombectomy~* Coronary brachytherapy treated patients~* Ejection fraction equal or minor to 30%~* Renal insufficiency (creatinine \>3.0 mg/dl)~* Warfarin-treated patients~* Life expectancy minor to 12 months~* Heart transplanted patients~* Patients still enrolled in some other study, both pharmacological both not

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
- No intervention (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The serum zinc concentrations are under the nomal level before registration~* Able to taking a tablet~Exclusion Criteria:~1. Heavy hepatitis~2. Malignant tumor~3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.~4. The serum albumin under 2.8 g/dL~5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)~6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration~7. Pregnant, suspected pregnant, lactating, patients who wish to have a child~8. Patient who participated in other clinical trials within 12 weeks before registration~9. Unsuitable as a target of this clinical trial judged by doctor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPC-02 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have completed all doses of study drug and Week 24 visit of the lead-in study.~* Women of childbearing potential who are sexually active, must agree to use at least one accepted method of contraception throughout the study, including 20 weeks after last dose of study drug is given.~* Women of childbearing potential must have a negative urine pregnancy test at Baseline (Week 0/V1).~* Participants must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study specific procedures.~* Participant is judged to be in good health as determined by the Investigator.~Exclusion Criteria:~* Female participant who is pregnant, breastfeeding or is considering becoming pregnant during study participation, including 20 weeks after the last dose of study drug is given.~* Premature discontinuation of the study drug in the lead-in study for any reason.~* Use of a biologic treatment other than risankizumab since first dose of study drug in the lead-in study.~* Time elapsed is \> 8 weeks since the Week 24 visit in the lead-in study.~* Active systemic infections during the last 2 weeks (exception: common cold) prior to the first dose, as assessed by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic Lumbar Spinal Stenosis (LSS) primarily caused by dorsal element hypertrophy.~* Prior failure of conservative therapy and ODI Score \>20%.~* Radiologic evidence of LSS (L3-L5), Ligamentum flavum \>2.5mm, confirmed by pre-op MRI and/or CT.~* Central canal cross sectional area ≤ 100 square mm.~* Anterior listhesis ≤ 5.0mm.~* Able to walk at least 10 feet unaided before being limited by pain.~* Available to complete 26 weeks of follow-up.~* A signed Informed Consent Form is obtained from the patient.~* Adults at least 18 years of age.~Exclusion Criteria:~* Prior surgery at intended treatment level.~* History of recent spinal fractures with concurrent pain symptoms.~* Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.)~* Significant / symptomatic disc protrusion or osteophyte formation.~* Excessive / symptomatic facet hypertrophy.~* Bleeding disorders and/or current use of anti-coagulants.~* Use of ASA and/or NSAID within 5 days of treatment.~* Pregnant and/or breastfeeding.~* Epidural steroids previously administered (not ESI naive)~* Wound healing pathologies deemed to compromise outcomes, including: diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.~* Dementia and/or inability to give informed consent.~* Inability of the patient to lie prone for any reason with anesthesia support (e.g. COPD, obesity, etc.).~* On Workman's Compensation or considering litigation associated with back pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vertos mild® Minimally-Invasive Lumbar Decompression (Type: ACTIVE_COMPARATOR): Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
- Epidural Steroid Injection (Type: ACTIVE_COMPARATOR): Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient \> 18 years undergoing a 2-4 level Anterior Cervical Discectomy and Fusion~Exclusion Criteria:~* Patients undergoing revision surgery~* Pediatric patients~* Trauma patients with cervical spine fractures~* Patients with cancer~* Patients with active infection~* Patients with a known allergy to Methylprednisolone Acetate~* Patients who refuse to participate~* Non English speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
- Control (Type: PLACEBO_COMPARATOR): Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months or HBsAg positive \> 3 months and positive for immunoglobulin G antibody against hepatitis B core antigen~* 18 through 69 years of age, inclusive~* Hepatitis B e antigen (HBeAg) positive~* HBV DNA ≥ 10\^8 copies/mL~* ALT ≤ the upper limit of the normal range (ULN)~* Willing and able to provide written informed consent~* Negative serum beta-human chorionic gonadotropin (for females of childbearing potential only)~* Calculated creatinine clearance ≥ 70 mL/min~* Hemoglobin ≥ 10 g/dL~* Neutrophils ≥ 1,500/mm\^3~* No prior oral HBV therapy (eg, nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)~Exclusion Criteria:~* Pregnant women, women who were breast feeding, or who believed they may have wished to become pregnant during the course of the study~* Males and females of reproductive potential unwilling to use an effective method of contraception during the study~* Decompensated liver disease defined as direct (conjugated) bilirubin \> 1.2 x ULN, prothrombin time \> 1.2 x ULN, platelets \< 150,000/mm\^3, serum albumin \< 3.5 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, or variceal hemorrhage)~* Received interferon (pegylated or not) therapy within 6 months of the screening visit~* Alpha-fetoprotein \> 50 ng/mL~* Evidence of hepatocellular carcinoma~* Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus~* Significant renal, cardiovascular, pulmonary, or neurological disease~* Received solid organ or bone marrow transplantation~* Was currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion~* Had proximal tubulopathy~* Known hypersensitivity to the study drugs, the metabolites, or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Tenofovir DF (Type: EXPERIMENTAL): Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
- FTC+Tenofovir DF (Type: EXPERIMENTAL): Participants were randomized to receive FTC plus tenofovir DF once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Effects of a Holistic Yoga Program and a Wellness Program on PTSD Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Veterans and civilians will be eligible for inclusion if~* they are age 18 or older,~* have a Clinician Administered PTSD Scale-confirmed PTSD diagnosis,~* and access to a working telephone for ease of contact during the course of the study.~Exclusion Criteria:~Exclusion criteria will include:~* severe medical conditions in which yoga is contraindicated;~* active psychosis;~* active suicidal intent;~* moderate to severe cognitive impairment as determined by the short Mini-Mental State Examination, a six-item screener (MMSE);~* involvement in ongoing yoga classes and/or regular home practice of yoga in the previous 3 months;~* and receiving ongoing medical or psychological treatment that includes more than one hour weekly of relaxation and mind-body based stress reduction strategies (related directly to meditation and yoga).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Holistic Yoga Program (Type: EXPERIMENTAL): The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
- Wellness Lifestyle Program (Type: ACTIVE_COMPARATOR): The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females between the ages of 18 and 75 who are diagnosed with mild to moderate Crohn's disease (defined by a CDAI \[Crohn's Disease Activity Index\] score of 220 and 450)~* Normal lab parameters~* Are willing to give informed consent~* Have previously used and either were intolerant to or lost response to infliximab~Exclusion Criteria:~* History of certain types of cancer~* Diagnosis of ulcerative colitis~* Pregnant female or breast feeding subjects~* Known obstructive strictures~* Surgical bowel resection in the past 6 months~* History of listeria, human immunodeficiency virus (HIV), central nervous system demyelinating disease or untreated TB (tuberculosis)~* History of poorly controlled medical conditions~* Specific doses and durations of Crohn's medications~* Subjects that have previously used infliximab and have never clinically responded unless primary non-response was due to a treatment limiting reaction to infliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete